Autopsy report · NCT02287025
A Phase 4 Study of Regorafenib in Metastatic Colorectal Cancer - Does Educating Physicians Change Patient Outcomes?
Cause of deathNo reason given
Life of this trial
- Registered 1 month before it started.
- Ran for about 1 year 5 months before it stopped.
- 23 participants enrolled.
- Results were posted on the registry 1 year 6 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 4
- Sponsor
- Bayer
- Sponsor type
- Industry
- Conditions
- Physician Education
- Interventions
- Regorafenib (Stivarga, BAY73-4506); iPAD application; Bayer specialist
- Participants
- 23
- Sites
- 17
- Countries
- United States
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.